(Q45340125)

13 December 2017

Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation (English)

1 reference

13 December 2017

0 references

W Zhao

1

1 reference

13 December 2017

Y H Gu

2

1 reference

13 December 2017

R Song

3

1 reference

13 December 2017

B Q Qu

4

1 reference

13 December 2017

Q Xu

5

1 reference

13 December 2017

13 March 2008

1 reference

13 December 2017

1 reference

13 December 2017

22

1 reference

13 December 2017

6

1 reference

13 December 2017

1226-1233

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2008.58

13 December 2017

0 references

cites work

BAY 43-9006: preclinical data

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.58

7 January 2021

Kinase inhibition with BAY 43-9006 in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.58

7 January 2021

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.58

7 January 2021

Antitumor activity of sorafenib in FLT3-driven leukemic cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.58

7 January 2021

The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.58

7 January 2021

Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.58

7 January 2021

Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.58

7 January 2021

Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.58

7 January 2021

Ro 09-2210 exhibits potent anti-proliferative effects on activated T cells by selectively blocking MKK activity.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.58

7 January 2021

Spontaneous regression of metastatic renal cancer. Case report and literature review

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.58

7 January 2021

T-cell activation through the antigen receptor. Part 1: signaling components, signaling pathways, and signal integration at the T-cell antigen receptor synapse

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.58

7 January 2021

Expansion of activated human naïve T-cells precedes effector function.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.58

7 January 2021

Receptor-associated constitutive protein tyrosine phosphatase activity controls the kinase function of JAK1.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.58

7 January 2021

Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.58

7 January 2021

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.58

7 January 2021

https://api.crossref.org/works/10.1038%2FLEU.2008.58

1 reference

7 January 2021

Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.58

7 January 2021

Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.58

7 January 2021

Identifiers

DOI

10.1038/LEU.2008.58

1 reference

Dimensions Publication ID

13 December 2017

0 references

1 reference